Angelini Pharma Partners with Cureverse on Brain Health Asset CV-01

Angelini Pharma, a division of Angelini Industries, and Cureverse Inc., a startup company, revealed they have signed a unique worldwide option contract to develop and market Cureverse's groundbreaking brain health asset CV-01. According to the agreement, Angelini Pharma will take charge of the development of CV-01 and may secure the exclusive global license for its development and commercialization, except in certain Asian regions. 

CV-01 is a new and creative investigational substance that triggers defense mechanisms controlled by the nuclear factor erythroid 2-related factor 2 (Nrf2) and could potentially be a therapeutic treatment with disease-altering effects for various brain disorders, such as epilepsy. CV-01, developed by Cureverse, is currently in phase 1 clinical trials in South Korea as an experimental treatment for Alzheimer's disease.

Cureverse will get an initial payment and may also receive extra payments based on specific development and commercial milestones, totaling approximately. $360 million, along with graduated royalties on net sales after approval.

“Our strategic collaboration with Cureverse further strengthens Angelini Pharma’s position as an emerging leader in brain health” said Jacopo Andreose, chief executive officer of Angelini Pharma. “Neurological conditions such as epilepsy are among leading causes of disease burden worldwide. While significant progress has been achieved in the past 15 years, many people living with epilepsy are still unable to reach seizure control despite combination treatment of several anti-seizure medications. Through the development of CV-01 and potentially other compounds, we aim to provide much-needed solutions for people living with brain health conditions across the world.”